IMMX

Immix Biopharma, Inc. [IMMX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMMX Stock Summary

Top 10 Correlated Stocks

IMMX

In the News

IMMX Financial details

Company Rating
-
Market Cap
72.85M
Income
-15.44M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-8.36
Forward P/E
-
PEG
-1.79
P/S
-1.4
P/B
5.98
P/C
-
P/FCF
-9.91
Quick Ratio
7.16
Current Ratio
7.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.91
EPS next Y
-
EPS next Q
-
EPS this Y
43.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
13.04%
-
-
-
-
SMA20
-5.42%
SMA50
-13.12%
SMA100
12.94%
Inst Own
-
Inst Trans
-
ROA
-63%
ROE
-98%
ROC
-0.74%
Gross Margin
100%
Oper. Margin
16%
Profit Margin
16%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.4-7.75
52W High
-74.86%
52W Low
+76%
RSI
31.76
Rel Volume
0.28
Avg Volume
283.91K
Volume
80.32K
Perf Week
-10.66%
Perf Month
-22.81%
Perf Quarter
-20.72%
Perf Half Y
-22.81%
-
-
-
-
Beta
0.049
-
-
Volatility
0.09%, 0.09%
Prev Close
-1.12%
Price
1.76
Change
-7.37%

Something similar

Top by Market Cap
BRH.DE
FXAIX
AMZN
CMC.DE
DHR-PB
Same Sector
INDP
KMDA
KALV
IDP.DE
AFIB
Top Correlated Stocks
FGBI
KIKOY
ICCH
0H14.L
RILY
Similar Market Cap
RVNU
WEL
ATACX
8545.HK
CRRX.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 283.91K
  • Market Capitalization 72.85M
  • Employee 14
  • CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
  • Headquarters Los Angeles,CA,US
  • IPO Date 2021-12-16
  • Website https://www.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.